JP7765191B2 - 黄色ブドウ球菌のα毒素に特異的な抗体及びその使用 - Google Patents

黄色ブドウ球菌のα毒素に特異的な抗体及びその使用

Info

Publication number
JP7765191B2
JP7765191B2 JP2021051904A JP2021051904A JP7765191B2 JP 7765191 B2 JP7765191 B2 JP 7765191B2 JP 2021051904 A JP2021051904 A JP 2021051904A JP 2021051904 A JP2021051904 A JP 2021051904A JP 7765191 B2 JP7765191 B2 JP 7765191B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021051904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021155416A5 (enExample
JP2021155416A (ja
Inventor
チャオ ツー－ユアン
チャン チン－ウェン
ツァオ エリック
Original Assignee
シナモア バイオロジクス（スーチョウ）カンパニー，リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シナモア バイオロジクス（スーチョウ）カンパニー，リミティッド filed Critical シナモア バイオロジクス（スーチョウ）カンパニー，リミティッド
Publication of JP2021155416A publication Critical patent/JP2021155416A/ja
Publication of JP2021155416A5 publication Critical patent/JP2021155416A5/ja
Application granted granted Critical
Publication of JP7765191B2 publication Critical patent/JP7765191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G01N2333/3156—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae [Pneumococcus]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2021051904A 2020-03-25 2021-03-25 黄色ブドウ球菌のα毒素に特異的な抗体及びその使用 Active JP7765191B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994744P 2020-03-25 2020-03-25
US62/994,744 2020-03-25

Publications (3)

Publication Number Publication Date
JP2021155416A JP2021155416A (ja) 2021-10-07
JP2021155416A5 JP2021155416A5 (enExample) 2024-03-12
JP7765191B2 true JP7765191B2 (ja) 2025-11-06

Family

ID=75223147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021051904A Active JP7765191B2 (ja) 2020-03-25 2021-03-25 黄色ブドウ球菌のα毒素に特異的な抗体及びその使用

Country Status (8)

Country Link
US (1) US11530256B2 (enExample)
EP (1) EP3895762A3 (enExample)
JP (1) JP7765191B2 (enExample)
KR (1) KR20210119913A (enExample)
CN (4) CN113444173A (enExample)
BR (1) BR102021005680A2 (enExample)
SG (1) SG10202103015VA (enExample)
TW (1) TWI877334B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN115785281B (zh) * 2022-09-27 2024-07-19 兴盟生物医药(苏州)有限公司 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用
CN117771379B (zh) * 2023-10-25 2024-08-30 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501506A (ja) 2009-08-10 2013-01-17 ケンタ バイオテク アーゲー 黄色ブドウ球菌由来のα毒素に対するヒトモノクローナル抗体、及び膿瘍形成の治療又は予防におけるその使用
JP2019011329A (ja) 2011-02-08 2019-01-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US20140286960A1 (en) 2011-07-28 2014-09-25 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US20160244511A1 (en) * 2013-10-17 2016-08-25 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN109384844B (zh) 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
CN109400704B (zh) 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN110437334B (zh) 2019-07-26 2020-12-01 西南医科大学 全人源抗金黄色葡萄球菌α-溶血素重组抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501506A (ja) 2009-08-10 2013-01-17 ケンタ バイオテク アーゲー 黄色ブドウ球菌由来のα毒素に対するヒトモノクローナル抗体、及び膿瘍形成の治療又は予防におけるその使用
JP2019011329A (ja) 2011-02-08 2019-01-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
岡山医学会雑誌，2009年，第121巻，pp. 119-122

Also Published As

Publication number Publication date
CN113444171A (zh) 2021-09-28
EP3895762A3 (en) 2022-01-12
CN113444174A (zh) 2021-09-28
BR102021005680A2 (pt) 2022-03-08
EP3895762A2 (en) 2021-10-20
CN113444172A (zh) 2021-09-28
CN113444173A (zh) 2021-09-28
SG10202103015VA (en) 2021-10-28
CN113444174B (zh) 2025-11-28
US11530256B2 (en) 2022-12-20
TW202202519A (zh) 2022-01-16
KR20210119913A (ko) 2021-10-06
TWI877334B (zh) 2025-03-21
US20210317193A1 (en) 2021-10-14
JP2021155416A (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
US11447543B2 (en) Antibodies to S. aureus surface determinants
JP6723293B2 (ja) 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP6182152B2 (ja) 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
AU2015276938B2 (en) Treatment of polybacterials infections
JP7765191B2 (ja) 黄色ブドウ球菌のα毒素に特異的な抗体及びその使用
AU2014270598B2 (en) Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
CN112672788A (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
JP2016535985A (ja) 交差反応性黄色ブドウ球菌抗体配列
CA3115633A1 (en) Combinations of anti-staphylococcus aureus antibodies
KR20170136637A (ko) 항-스타필로코커스 아우레우스 항체 배합 제제
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
HK40025295A (en) Antibodies to s. aureus surface determinants
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體
HK1215054B (en) Antibodies to s. aureus surface determinants

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251024

R150 Certificate of patent or registration of utility model

Ref document number: 7765191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150